Skip to content

New drug for MDR-TB does well in trial

`Shock and kill` approach awakens latent HIV in test tube

Glaxo to test rival's protease inhibitor, re-engineered to last longer

Raltegravir shows potential for use as PrEP drug

GSK and Pfizer HIV divisions to form new company

Breakthrough in XDR-TB research could lead to two-drug treatment

Two novel ‘enhancer’ drugs boost protease inhibitors as much as ritonavir

Panacos sells its first-in-class maturation inhibitor

Gilead aiming to put four HIV drugs in one pill